| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2 Data readout example | LB-100 Ovarian clear cell cancer | Phase 1B/2 | — | Small Molecules | Oncology | ||
Phase 1b/2 Data readout example | LB-100 Ovarian clear cell cancer | Phase 1B/2 | — | Small Molecules | Oncology | ||
Phase 1b/2 Data readout example | LB-100 Ovarian clear cell cancer | Phase 1B/2 | — | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Lixte Biotechnology Holdings, Inc.$7.24
+0.36 (+5.23%)
D 20Pipeline Score Richly Valued Biotech · Clinical
Market Cap
72.81 M
EPS
-1.12
P/E Ratio
-
Value Trade
1.66 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
333.38 K
Operating CF
-1.83 M
Total Assets
10.87 M
Total Liabilities
1.69 M
Equity
7.95 M
D/E Ratio
12,345
8.09 %
Week
65.87 %
1 Month
86.67 %
3 Month
31.84 %
6 Month
-78.92 %
5 Year
-90.3 %
All Time
Cash Data
Cash Position
3.25 M
Monthly Burn
610.00 K
Runway
4.4 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
105.39 K
52 Week Range
0.64 - 6.26
% held by Insiders
12.02 %
% held by Institutions
4.21 %
Enterprise Value
71.85 M
Total Shares
11.62 M
Short %
2.13 %
Float Shares
11.61 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D20
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 19%
Micro Cap (rank 734 of 905)
Percentile RankLixte Biotechnology Holdings, Inc. faces pipeline headwinds (20/100), with $47M risk-adjusted pipeline value, led by LB-100 in Tumors (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LB-100 Small molecule | Myelodysplastic Syndromes | Phase 1 | NCT03886662 | 22% | $47M | RECRUITING | 47 | STALLED | F (17) | Jul 1, 2021 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LIXT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Lixte Biotechnology Holdings, Inc. (LIXT) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
LIXT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIXT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIXT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIXT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LIXT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LIXTLIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
LIXTE Biotechnology Holdings, Inc. has announced its acquisition of NOMAD Transportable Power Systems, a leader in mobile battery energy storage systems. This strategic move aims to address the growing demand for reliable electrical power amid a power availability crisis. Following the acquisition, the company will be renamed NOMAD Power Solutions, focusing on scalable infrastructure for energy solutions.
Read more →LIXTLIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
LIXTE Biotechnology has filed its Q1 2026 report, highlighting advancements in its lead compound LB-100, which shows synergy with existing cancer treatments. The company is expanding its ovarian cancer trial following positive safety results. Additionally, the acquisition of Liora Technologies is expected to enhance its capabilities in proton therapy. LIXTE remains focused on innovative cancer therapies and strategic growth.
Read more →LIXTFavorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
LIXTE Biotechnology Holdings presented preliminary results from a clinical trial combining LB-100 with Dostarlimab at the Society of Gynecological Cancer Conference. The findings indicate a promising safety profile and efficacy for ovarian cancer patients, with a disease control rate of 40%. An additional cohort is being enrolled to further assess the treatment's potential.
Read more →LIXTLIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
LIXTE Biotechnology Holdings has filed its Annual Report on Form 10-K for 2025, highlighting a transformative year. The company advanced its lead compound LB-100 and completed a strategic acquisition. Additionally, LIXTE raised capital to strengthen its balance sheet, positioning itself for future growth and innovation in cancer treatments.
Read more →LIXTLIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
LIXTE Biotechnology has appointed Sidney Braun as CEO of its subsidiary, Liora Technologies Europe Ltd. Braun brings over 20 years of experience in the healthcare sector and was instrumental in Liora's establishment. His leadership is expected to advance Liora's innovative LiGHT System technology, aimed at improving cancer treatment outcomes.
Read more →LIXTDE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE
The Good Health: Mind, Body & Soul Summit, sponsored by LIXTE Biotechnology, will be held on February 19 at Morehouse College. This invitation-only event aims to promote health equity for Black men and families, featuring discussions on various health topics. De La Soul's involvement emphasizes the connection between music, culture, and wellness.
Read more →LIXTLIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
LIXTE Biotechnology Holdings, Inc. will attend the DealFlow Discovery Conference on January 28-29, 2026, in Atlantic City, New Jersey. CEO Geordan Pursglove will hold one-on-one meetings with investors. The company is focused on developing LB-100, a first-in-class cancer therapy, which is currently in clinical trials for various cancer types.
Read more →LIXTLIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
LIXTE Biotechnology Holdings is expanding its clinical trial for ovarian clear cell cancer by doubling the patient enrollment from 21 to 42. The trial, which combines LIXTE's LB-100 with GSK's Dostarlimab, aims to enhance immunotherapy effectiveness. Initial findings are expected to be presented in the first half of 2026, reflecting the company's commitment to innovative cancer treatments.
Read more →LIXTLIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3
LIXTE Biotechnology Holdings will present at the Spartan Capital Investor Conference on November 3, 2025. CEO Geordan Pursglove will discuss the company's lead compound, LB-100, a novel cancer therapy. The conference will facilitate one-on-one meetings with investors, highlighting LIXTE's commitment to advancing cancer treatment options.
Read more →LIXTLIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans
LIXTE Biotechnology Holdings has outlined its priorities for Q4 2025, focusing on the advancement of its lead candidate LB-100 and strategic acquisitions in oncology. The company is in advanced negotiations for potential acquisitions to enhance its pipeline. LB-100 has shown promise in clinical trials for various cancer types, but the company acknowledges the risks associated with its forward-looking statements.
Read more →LIXTLIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
LIXTE Biotechnology Holdings has appointed Lourdes Felix and Guy Primus to its Board of Directors and named Peter Stazzone as the new Chief Financial Officer. The company has also relocated its corporate headquarters to Boca Raton, aiming to enhance operational efficiency. The new appointments are expected to strengthen LIXTE's focus on developing innovative cancer therapies.
Read more →LIXTLIXTE Biotechnology Holdings Provides Corporate Update
LIXTE Biotechnology Holdings has provided a corporate update highlighting significant developments, including the completion of two financings that raised $6.5 million and regaining compliance for Nasdaq listing. The company announced management changes, the formation of a scientific advisory committee, and published new findings in Nature that support its ongoing clinical trials with LB-100. Additionally, LIXTE has launched a new pre-clinical study.
Read more →LIXTLixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering
Lixte Biotechnology Holdings, Inc. has successfully closed a registered direct offering, raising approximately $1.5 million through the sale of shares of Common Stock. The offering price was set at $1.54 per share, with proceeds expected to be used for general corporate purposes. The transaction was facilitated by Spartan Capital Securities, LLC.
Read more →LIXTLixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
Lixte Biotechnology Holdings, Inc. has successfully closed a $5.0 million private placement with accredited investors. The offering included shares of Common Stock, Series B Convertible Preferred Stock, and Common Warrants. The funds will be utilized for general corporate purposes and working capital. The transaction closed on July 2, 2025, with Spartan Capital Securities acting as the exclusive placement agent.
Read more →Competitive Position
How LIXT ranks across every disease it competes inCompetitive Position is a premium feature
See how LIXT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial